Case Note & Summary
The case involved appeals against the Allahabad High Court's decision rejecting a writ petition challenging the validity of notifications that imposed ceiling prices on drug formulations, specifically Frusemide. The appellants, M/S T.C. Healthcare P. Ltd. and Modi Mundipharma Pvt. Ltd., were small scale units exempt from price fixation under the Drugs (Price Control) Order, 1995 (DPCO). They contended that the price fixation was arbitrary and did not consider the cost and efficiency of major manufacturers. The High Court found that the Central Government had conducted a thorough price fixation process, including gathering data from various pharmaceutical producers. The appellants argued that the technologies used in their products were not covered by the existing price norms, but the court noted that the appellants failed to demonstrate any unique aspects of their formulations. Ultimately, the Supreme Court upheld the High Court's decision, dismissing the appeals without costs.
Headnote
A) Administrative Law - Price Fixation - Legislative Nature of Price Fixation - Drugs (Price Control) Order, 1995 - The court held that price fixation is a legislative exercise and does not require individual notice to manufacturers. The High Court's reliance on the legislative nature of the process was upheld, affirming the validity of the notifications issued (Paras 5-6).
Issue of Consideration
Whether the notifications imposing ceiling prices on drug formulations were ultra vires the Drugs (Price Control) Order, 1995.
Final Decision
The Supreme Court dismissed the appeals, affirming the High Court's decision that the notifications were valid and did not require individual notice to manufacturers.
Law Points
- price fixation
- drug formulation
- small scale units
- Drugs (Price Control) Order
- 1995
- ceiling prices
- legislative exercise
